Nexavar
Nexavar Official FDA information, side effects and uses.
Onyx shares up after Bayer announces Nexavar sales - Reuters
Posted by Nexavar (Nexavar) on Tue, 21 Aug 2007 23:19:45 +0000
TFN NEWS BRIEFING: Pharmaceuticals and chemicals highlights to 15 ... - Hemscott
Bayer: sales growth from Schering but future focus on Nexavar - Pharmaceutical Business Review
Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2007 ... - CNNMoney.com
Onyx Is Almost There - Motley Fool
Posted by Nexavar (Nexavar) on Tue, 21 Aug 2007 23:19:45 +0000
Onyx shares up after Bayer announces Nexavar sales Reuters - DE: Quote, Profile, Research) reported a 161 rise in sales of their cancer drug Nexavar. Shares in Emeryville, California-based Onyx, which is scheduled to ... |
TFN NEWS BRIEFING: Pharmaceuticals and chemicals highlights to 15 ... - Hemscott
TFN NEWS BRIEFING: Pharmaceuticals and chemicals highlights to 15 ... Hemscott, UK - LEVERKUSEN, Germany (Thomson Financial) - Bayer AG and US company Onyx Pharmaceuticals Inc said their application for Nexavar to be approved as a treatment ... |
Bayer: sales growth from Schering but future focus on Nexavar - Pharmaceutical Business Review
Bayer: sales growth from Schering but future focus on Nexavar Pharmaceutical Business Review - However, the leading German pharmaceutical company's future focus relies heavily on the new oncology treatment Nexavar. 'Content The 'Bayer Group' which ... |
Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2007 ... - CNNMoney.com
Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2007 ... CNNMoney.com - Nexavar net revenue was $81.3 million for the quarter ended June 30, 2007, which represents more than a 150% increase over the $32.2 million reported in the ... |
Onyx Is Almost There - Motley Fool
Onyx Is Almost There Motley Fool - Sales of Nexavar began to stagnate in the first quarter, as it ran into competition from Pfizer's (NYSE: PFE) Sutent, but an upswing returned in the second ... |
